Abstract 158P
Background
C-reactive protein/albumin (CRP/Alb) ratio has been identified to be associated with prognosis in pancreatic cancer. However, the role of it in biliary tract cancers has not been examined. The aim of this study is to assess the role of CRP/Alb in curatively resected extrahepatic bile duct cancers (EBDC).
Methods
We retrospectively analyzed 235 patients who underwent curative resection because of EBDC in Seoul National University Bundang Hospital between March 2005 and February 2018. The laboratory data including CRP and albumin levels were obtained by blood tests prior to surgery. The correlations among the preoperative CRP/Alb ratio, clinicopathological factors, and patient outcomes were investigated.
Results
Men were 143 (60.8%) and mean age was 68 years (range 41–85 years). EBDC perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). Median follow-up was 22 months and median recurrence free survival 17 months, respectively. The optimal prognostic cut-off point of the CRP/Alb ratio for tumor recurrence was 0.18. Multivariate logistic regression analysis for overall survival showed age older than 65 (HR 1.937; 95% CI 1.275–2.944; p = 0.002), advanced staging (Reference stage I, stage II - HR 1.963; 95% CI 1.261–3.056; p = 0.004, stage III - HR 2.158; 95% CI 1.155–4.031; p = 0.016), Increased CA 19-9 (HR 1.735; 95% CI 1.069–2.816; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.638; 95% CI 1.102–2.434; p = 0.015). Multivariate logistic regression analysis for recurrence free survival showed advanced staging (Reference stage I, stage II - HR 1.750; 95% CI 1.127–2.717; p = 0.013), venous invasion (HR 1.742; 95% CI 1.097–2.767; p = 0.019), perineural invasion (HR 2.427; 95% CI 1.114–5.287; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.702; 95% CI 1.144–2.531; p = 0.009).
Conclusions
Preoperative CRP/Alb ratio is significantly associated with recurrence and overall in patients with resected EBDC. Further studies are necessary to assess the role of preoperative CRP/Alb ratio in EBDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Bundang Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract